e-learning
resources
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ERS TASK FORCE REPORT. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
Philip H. Quanjer, Sanja Stanojevic, Tim J. Cole, Xaver Baur, Graham L. Hall, Bruce H. Culver, Paul L. Enright, John L. Hankinson, Mary S.M. Ip, Jinping Zheng, Janet Stocks and the ERS Global Lung Function Initiative
Source:
Guideline 2012
Number:
0
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Philip H. Quanjer, Sanja Stanojevic, Tim J. Cole, Xaver Baur, Graham L. Hall, Bruce H. Culver, Paul L. Enright, John L. Hankinson, Mary S.M. Ip, Jinping Zheng, Janet Stocks and the ERS Global Lung Function Initiative. ERS TASK FORCE REPORT. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Guideline 2012
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Gerald Zavorsky - 28.03.2023 20:30
The link to the supplement is not provided. The zip files are also no where to be found
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Verification of flow rate stability in high-flow nasal cannula devices
DLCO biological controls in clinical practice.
Related content which might interest you:
Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
Source: Eur Respir J 2012; 40: 1324-1343
Year: 2012
LATE-BREAKING ABSTRACT: All-age multi-ethnic reference values for spirometry: The global lung function initiative (GLI)
Source: Annual Congress 2012 - Predicting the future: the impact of reference values on a range of respiratory paramaters
Year: 2012
"REDUCED MITOCHONDRIAL DENSITY IN THE VASTUS LATERALIS MUSCLE OF PATIENTS WITH COPD". H.R. GOSKER, M.K.C. HESSELINK, H. DUIMEL, K.A. WARD AND A.M.W.J. SCHOLS. EUR RESPIR J 2007; 30: 73 79.
Source: Eur Respir J 2007; 30: 817
Year: 2007
RELATIONSHIP BETWEEN RESPIRATORY SYMPTOMS AND MEDICAL TREATMENT IN EXACERBATIONS OF COPD. EUR RESPIR J 2005; 26: 406-413.
Source: Eur Respir J 2006; 27: 440
Year: 2006
LATE-BREAKING ABSTRACT: ASSOCIATION OF SEVERE EXACERBATION WITH FEV1 DECLINE AND LOSS OF AIRWAY REVERSIBILITY IN ASTHMA
Source: International Congress 2014 – Asthma: still a heterogeneous condition!
Year: 2014
Lung attacks in the ED: measurements to predict outcome. The AWARD study.
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
The global Lund function initiative (GLI) reference values do not reflect lung function in the Nordic countries
Source: International Congress 2015 – Epidemiology of respiratory disease
Year: 2015
FOR PREPARATION: ERS abstract submission guidelines
Source:
Year: 2015
EOSINOPHIL COUNT AND FeNO AS PREDICTORS OF EXACERBACTIONS IN COPD
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
BODE INDEX IN DIFFERENT PHENOTYPES OF COPD
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
IMPACT OF SMOKE-FREE WORKPLACE LEGISLATION ON EXPOSURES AND HEALTH: POSSIBILITIES FOR PREVENTION. M.S. JAAKKOLA AND J.J.K. JAAKKOLA. EUR RESPIR J 2006; 28: 397-408.
Source: Eur Respir J 2006 Oct 01;28(4):887-888
Year: 2006
Canadian prediction equation of spirometric lung function for caucasian adults 18-90 years: Results from the Canadian obstructive lung disease (COLD) study and the Canadian ECRHS study
Source: Annual Congress 2011 - Respiratory epidemiology: methods, definitions and phenotypes
Year: 2011
"TACROLIMUS FOR ANTISYNTHETASE SYNDROME WITH INTERSTITIAL LUNG DISEASE?" [REPLY LETTER]. L.P. NICOD. EUR RESPIR J 2008; 32: 245-246.
Source: Eur Respir J 2008; 32: 822
Year: 2008
Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST
Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD
Year: 2021
"LUNG VOLUME MEASUREMENTS" [REPLY LETTER]. M. CAZZOLA, V. BRUSASCO AND F.J. MARTINEZ. EUR RESPIR J 2008; 32: 528.
Source: Eur Respir J 2008; 32: 822
Year: 2008
TORVAN VERSUS GAP: WHICH PERFORMS BETTER?
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Classification of PFT data using global lung initiative (GLI) and national health and nutrition examination survey (NHANES-III) models when extrapolated beyond the NHANES-III limit of 80 years of age
Source: Annual Congress 2013 –Reference, reliability and risk: advances in lung function
Year: 2013
The recent multi-ethnic global lung initiative 2012 (GLI
2012
) reference values don’t reflect contemporary Mediterranean spirometry
Source: Annual Congress 2013 –Early diagnosis and effectiveness of disease management in primary care
Year: 2013
BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION? EUR RESPIR J 2005; 26: 819-828.
Source: Eur Respir J 2005; 26: 1191
Year: 2005
CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept